Druck Icon

Eckert & Ziegler raises profit expectations

(Ad hoc press release)

Berlin, June 30, 2015 – The sale of the shares in Berlin-based OctreoPharm Sciences GmbH to the French pharmaceuticals company IPSEN took legal effect today following the receipt of an initial payment. As a result, the Executive Board of Eckert & Ziegler AG has raised its profit forecast for 2015 to at least € 2.00 per share, or just over € 10 million. The new forecast is based on the probability-weighted anticipated income from the sale of the shares as well as current developments in the first half of the year.

More detailed information on the effect of the sale of shares on profits as well as the complete results for the first half of the year will be released as scheduled on August 4, 2015.

For enquiries, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de